Bluejay Diagnostics Inc (BJDX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are mixed, with bearish moving averages and no clear upward momentum. Additionally, the company’s financial performance is weak, with significant declines in net income and EPS. There are no positive news catalysts, trading trends, or signals from Intellectia Proprietary Trading Signals to suggest an immediate buying opportunity. Holding or exploring other investment opportunities may be more prudent.
The MACD is positive and expanding, which is a bullish signal. However, the RSI is neutral at 58.127, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 1.928, with resistance at 2.081 and support at 1.776. Overall, the technical indicators do not suggest a strong buy signal.
NULL identified. No recent news, no significant hedge fund or insider trading activity, and no recent congress trading data.
Weak financial performance in the latest quarter, with a significant drop in net income (-90.24% YoY) and EPS (-61.96% YoY). No positive trading trends or news catalysts.
In Q4 2025, revenue remained at 0 with no growth YoY. Net income dropped significantly to -1,429,812 (-90.24% YoY), and EPS declined to -42.32 (-61.96% YoY). Gross margin remained at 0 with no improvement.
No data on analyst ratings or price target changes available.
